REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2019.11.12 | 07:25 | Permanent Information Releases / General Company News

puce Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment - HTML (w)

2019.11.12 | 07:15 | Permanent Information Releases / General Company News

puce New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis - HTML (w)

2019.11.11 | 07:00 | Permanent Information Releases / General Company News

puce Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market - HTML (w)

2019.11.05 | 07:15 | Permanent Information Releases / General Company News

puce Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez) - HTML (w)

2019.11.01 | 07:15 | Permanent Information Releases / General Company News

puce Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis - HTML (w)

2019.10.30 | 07:00 | Permanent Information Releases / General Company News

puce Novartis announces AVXS-101 intrathecal study update - HTML (w)

2019.10.24 | 07:15 | Permanent Information Releases / General Company News

puce Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis - HTML (w)

2019.10.22 | 07:00 | Permanent Information Releases / General Company News

puce Novartis verzeichnet ein weiteres starkes Quartal mit zweistelligem Umsatz-wachstum und höherer Kerngewinnmarge1; Umsatz- und Gewinnerwartung für 2019 angehoben; US-Einführung von Beovu - HTML (w)

2019.10.22 | 07:00 | Permanent Information Releases / General Company News

puce Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US - HTML (w)

2019.10.22 | 07:00 | Permanent Information Releases / General Company News

puce Novartis, encore un fort trimestre: croissance à deux chiffres des ventes et expansion de la marge core1; hausse des prévisions de chiffre d’affaires et de résultat en 2019; Beovu lancé aux USA - HTML (w)

2019.10.08 | 07:15 | Permanent Information Releases / General Company News

puce Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept - HTML (w)

2019.10.08 | 07:15 | Permanent Information Releases / General Company News

puce Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept - HTML (w)

2019.10.02 | 07:15 | Permanent Information Releases / General Company News

puce Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum - HTML (w)

2019.10.01 | 16:00 | Permanent Information Releases / General Company News

puce Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence - HTML (w)

2019.09.30 | 07:20 | Permanent Information Releases / General Company News

puce Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1257